2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Assays, Imaging, Molecular Testing, Treatment Considerations, Combination Therapy, Biological Therapies, Transplantation, Immunotherapy, Non-Biological Therapies, Chemotherapy, Adverse Events, Biological Processes, Pathogenesis, CHIP, Immune Mechanism, Clinical Practice (Health Services and Quality), Clinical Guidelines, Diseases, Infectious Diseases, Viral, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, LGL, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, B Cell Lymphoma, T Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, Translational Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Real-World Evidence, Study Population, Human, Adult
PAPER

3598 Clonal hematopoiesis identifies a high-risk clinical phenotype in cutaneous T-cell lymphoma

Jee Hyuk Byun, MD, Chelsea Kim2, Kernyu Park, MS3, Eunyoung Kim4, Darina Paulino5, Saja Kadhim Asakrah,, MD6, Pamela Allen, MD7, Janghee Woo, MD, PhD8
1 Emory Winship Cancer Institute, Atlanta, Georgia, United States
2 Emory Winship Cancer Institute, Atlanta, Georgia, United States
3 Emory Winship Cancer Institute, Atlanta, Georgia, United States
4 Emory Winship Cancer Institute, Atlanta, Georgia, United States
5 Emory Winship Cancer Institute, Atlanta, Georgia, United States
6 Emory Winship Cancer Institute, Atlanta, Georgia, United States
7 Emory Winship Cancer Institute, Atlanta, Georgia, United States
8 Emory Winship Cancer Institute, Atlanta, Georgia, United States
Clonal hematopoiesis (CH), the expansion of hematopoietic clones harboring somatic mutations, is associated with adverse outcomes across multiple malignancies. Common CH mutations, including TET2 and DNMT3A, can remodel the immune microenvironment and alter T-cell differentiation and function. Cutaneous T-cell lymphoma (CTCL) is characterized by profound immune dysregulation, skin-barrier disruption, and susceptibility to Staphylococcus aureus infection. However, the prevalence and prognostic significance of CH in CTCL remain unknown. We investigated whether CH identifies patients with CTCL at increased risk of death.

We analyzed 49 patients with CTCL who were treated and longitudinally followed at the Winship Cancer Institute of Emory University and underwent targeted peripheral-blood sequencing of 25 CH-associated genes. CH was defined by somatic variants with variant allele frequency ≥2%. Overall survival (OS) was measured from biospecimen collection and evaluated using Kaplan–Meier, log-rank, and Cox proportional-hazards analyses. Inverse probability of treatment weighting (IPTW) was used to account for age, sex, race, and disease stage. 

CH-associated mutations were identified in 15 of 49 patients (30.6%). Recurrently altered genes included DNMT3A, TET2, TP53, and ASXL1. No concurrent myeloid neoplasm was identified in patients with TP53 variants. CH-positive patients tended to be older than CH-negative patients (mean age, 66.8 versus 57.7 years; p=0.075), and the categorical age comparison approached statistical significance (p=0.051). Among CH-negative patients, 27 of 34 (79.4%) had mycosis fungoides (MF), 3 (8.8%) had Sézary syndrome (SS), and 4 (11.8%) had other CTCL subtypes. Among CH-positive patients, 11 of 15 (73.3%) had MF, 3 (20.0%) had SS, and 1 (6.7%) had another CTCL subtype. Neither subtype distribution (p=0.809) nor stage at diagnosis (p=0.670) differed by CH status. 

CH status was strongly associated with survival. After a median follow-up of 21 months (range, 0–180), 10 of 15 CH-positive patients (66.7%) had died compared with 8 of 34 CH-negative patients (23.5%; χ² p=0.010). CH-positive patients had significantly inferior OS (log-rank; p=0.0360), with an unweighted Cox HR for death at 2.61 (95% CI, 1.03-6.63; p=0.0432). The adverse association persisted after IPTW adjustment for age, sex, race, and disease stage (HR, 2.82; 95% CI, 1.10-7.22; p=0.0303), despite the absence of significant differences in CTCL subtype or stage between CH groups.

S. aureus history was available for 47 patients and did not differ by CH status (40.0% versus 50.0%; P=0.744). OS differed across the four joint CH/S. aureus groups in unadjusted (P=0.017) and IPTW-adjusted analyses (P=0.035), with the greatest mortality risk observed in CH-positive patients regardless of S. aureus history. The CH × S. aureus interaction was not significant (P=0.252), providing no evidence that S. aureus modified the association between CH and OS. Paired CTCL-tissue sequencing is ongoing to define the lineage and tissue distribution of detected variants.

To our knowledge, this is the first study to demonstrate a survival disadvantage associated with CH in CTCL. CH was common and associated with an approximately threefold increased risk of death independent of age, sex, race, and disease stage. This association was not explained by CTCL subtype. These findings identify CH as a clinically accessible, blood-based candidate biomarker for refining risk stratification and surveillance in CTCL. Larger, lineage-resolved studies are warranted to determine how CH-associated inflammatory and immune programs influence CTCL progression and treatment response.
Jee Hyuk Byun, MD: Proteina - Consultancy (Includes expert testimony)